Clinical trial NCT05228704: Study on the Influence of Forest Therapy on Healing Experience in Botanical Gardens.
Official title: Study on the Influence of Forest Therapy on Healing Experience in Botanical Gardens.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Nature, Human
Keywords: Forest therapy
Lead sponsor: Taipei City Hospital
Sponsor class: OTHER_GOV
First posted: 2022-02-08
Enrollment: 42
Sex: ALL
Minimum age (years): 20
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The forest healing system is an important topic of alternative therapy in recent years. To study the influence of Forest therapy, the establishment of a pilot experimental model system in which both environmental factors and type of activity are necessary. Therefore, a system based on the Taipei Botanical Garden was introduced by this study.

Detailed description: The forest healing system is an important topic of alternative therapy in recent years. Forest therapy began in 1989 when the psychology professor Kaplan put forward the "Attention Restoration Theory(ART)". Awareness has a positive benefit. To study the influence of Forest therapy, the establishment of a pilot experimental model system in which both environmental factors and type of activity are controlled can greatly reduce the errors caused by the site and the content of the activity. Therefore, a randomized controlled crossover experiment based on the Taipei Botanical Garden was introduced by this study.

Eligibility criteria: Inclusion Criteria:

* 20-35 years old youth (not limited to men and women)
* Those who have the ability and physical strength to walk for more than 120 minutes
* Subjects must voluntarily join the study

Exclusion Criteria:

* People who smoke or chew betel nuts
* People who have the habit of drinking (drinking more than five standard glasses in any situation)
* Drug addiction (including narcotic drugs and non-narcotics) habitual
* Those who have taken psychosomatic drugs in the past 30 days
* Participating in another clinical trial at the same time, or in the follow-up period of an interventional trial
* Those diagnosed with major injuries
* Women who are currently pregnant or breastfeeding
* Conditions where other subjects cannot cooperate (for example: unable to participate after random assignment, and not signing the subject's consent form)

Primary outcomes:
measure: questionnaire: BPOMS (1st)
timeFrame: baseline, pre-intervention(1st) → 2 hours intervention → immediately after the intervention(1st)
measure: questionnaire: BPOMS (2nd)
timeFrame: pre-intervention(2nd) → 2 hours intervention → immediately after the intervention(2nd)
measure: questionnaire: BAI (1st)
timeFrame: baseline, pre-intervention(1st) → 2 hours intervention → immediately after the intervention(1st)
measure: questionnaire: BAI (2nd)
timeFrame: pre-intervention(2nd) → 2 hours intervention → immediately after the intervention(2nd)
measure: questionnaire: BDI-II (1st)
timeFrame: baseline, pre-intervention(1st) → 2 hours intervention → immediately after the intervention(1st)
measure: questionnaire: BDI-II (2nd)
timeFrame: pre-intervention(2nd) → 2 hours intervention → immediately after the intervention(2nd)
measure: questionnaire: BSRS-V (1st)
timeFrame: baseline, pre-intervention(1st) → 2 hours intervention → immediately after the intervention(1st)
measure: questionnaire: BSRS-V (2nd)
timeFrame: pre-intervention(2nd) → 2 hours intervention → immediately after the intervention(2nd)
measure: physiological indicator: alpha-amylase activity in salivary (1st)
timeFrame: baseline, pre-intervention(1st) → 2 hours intervention → immediately after the intervention(1st)
measure: physiological indicator: alpha-amylase activity in salivary (2nd)
timeFrame: pre-intervention(2nd) → 2 hours intervention → immediately after the intervention(2nd)
measure: physiological indicator: HRV (Heart Rate Variability) (1st)
timeFrame: baseline, pre-intervention(1st) → 2 hours intervention → immediately after the intervention(1st)
measure: physiological indicator: HRV (Heart Rate Variability) (2nd)
timeFrame: pre-intervention(2nd) → 2 hours intervention → immediately after the intervention(2nd)
measure: physiological indicator: blood pressures (systolic and diastolic) (1st)
timeFrame: baseline, pre-intervention(1st) → 2 hours intervention → immediately after the intervention(1st)
measure: physiological indicator: blood pressures (systolic and diastolic) (2nd)
timeFrame: pre-intervention(2nd) → 2 hours intervention → immediately after the intervention(2nd)
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Taipei city hospital
Study officials:
affiliation: Branch of Chinese Medicine, Taipei City Hospital
name: Chung-Hua Hsu
role: STUDY_DIRECTOR
References: